Amanta Healthcare Reports Strong FY26 Results with 42% PAT Growth

Amanta Healthcare's Profit After Tax (PAT) for the fiscal year ended March 31, 2026, rose by over 42% to Rs 15 crore, up from Rs 11 crore in FY25. Revenue for FY26 stood at Rs 288 crore, a marginal increase from Rs 275 crore in the previous year.

Reader Takeaway: Profitability growth and debt reduction signal financial health, but single-site operations pose a risk.

What just happened

Amanta Healthcare announced its financial results for FY26, showcasing a significant 42% year-on-year growth in Profit After Tax (PAT) to Rs 15 crore. This was achieved on a revenue of Rs 288 crore. The company also reported commissioning a 10.8 MW captive solar power plant in Q1 FY27, which is projected to save Rs 9 crore annually. Furthermore, Amanta has made substantial progress in reducing its debt.

Why this matters

The strong PAT growth indicates improved operational efficiency and potentially lower finance costs. The commissioning of the solar plant is a strategic move towards cost optimization and enhancing its ESG profile. Significant debt reduction strengthens the company's balance sheet, making it more resilient.

The backstory

In FY23, Amanta Healthcare had a high Debt-to-Equity ratio of 3.43x. The company has been actively working on deleveraging its balance sheet over the past few years. The current fiscal year marks a significant turnaround in this aspect, with the ratio dropping to 1.06x by FY26.

What changes now

The focus on expanding capacity, particularly for SteriPort and SVP, along with efforts to enter regulated markets by meeting PIC/S and EU Annex 1 standards, suggests a push for future growth. The solar plant is expected to start contributing to cost savings immediately.

Risks to watch

Amanta's operations are concentrated at its single Kheda facility, making it vulnerable to any disruptions at this site. Additionally, revenue has a significant reliance on the SteriPort product (42-44%) and the domestic market (68%).

Peer comparison

While specific peer financial data for FY26 is not provided, Amanta's reported EBITDA margin of approximately 22% and a PAT growth of 42% indicate a potentially competitive performance. Companies in the pharmaceutical and healthcare sector often focus on expanding capacities and reducing operational costs, with many exploring renewable energy sources.

Context metrics (time-bound)

• Revenue FY26: Rs 288 crore (vs Rs 275 crore in FY25)
• PAT FY26: Rs 15 crore (vs Rs 11 crore in FY25)
• Debt-to-Equity Ratio FY26: 1.06x (down from 3.43x in FY23)
• Solar Plant Commissioned: Q1 FY27
• CSR Spend FY26: Rs 28.72 lakh

What to track next

Investors will be keen to observe the progress of capacity expansions, entry into new regulated markets, and the actual cost savings realized from the solar power plant. The upcoming 31st AGM will also be important for decisions regarding management remuneration.